蓮花健康(600186.SH)收到再審應訴通知書 涉案金額7957.5萬元及利息
格隆匯11月8日丨蓮花健康(600186.SH)公佈,公司於近日收到《中華人民共和國最高人民法院應訴通知書》﹝(2021)最高法民申7377號﹞。因借款合同糾紛,再審申請人惠大軍因不服河南省高級人民法院作出的(2020)豫民終1095號民事裁定,向最高人民法院遞交了《再審申請書》,法院現已受理。上市公司所處的當事人地位:被申請人(原審一審被吿、二審上訴人);涉案的金額:人民幣7957.5萬元及利息。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.